MacroGenics Inc. (NASDAQ:MGNX) shares fell 1.5% on Wednesday . The company traded as low as $30.26 and last traded at $30.81, with a volume of 81,072 shares changing hands. The stock had previously closed at $31.28.

A number of analysts have issued reports on MGNX shares. Morgan Stanley reaffirmed a “hold” rating on shares of MacroGenics in a report on Thursday, June 30th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of MacroGenics in a report on Tuesday, June 14th. Citigroup Inc. lowered MacroGenics from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $27.00 to $32.00 in a report on Thursday, August 4th. TheStreet raised MacroGenics from a “sell” rating to a “hold” rating in a report on Friday, August 5th. Finally, Zacks Investment Research lowered MacroGenics from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $38.71.

The company has a 50-day moving average of $30.49 and a 200-day moving average of $24.71. The company’s market capitalization is $1.09 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/macrogenics-inc-mgnx-shares-down-1-5.html

MacroGenics (NASDAQ:MGNX) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $1.14. MacroGenics had a negative return on equity of 10.65% and a negative net margin of 31.77%. The business had revenue of $80.67 million for the quarter, compared to analyst estimates of $27.22 million. During the same quarter in the prior year, the company posted ($0.71) earnings per share. MacroGenics’s revenue was up 1100.4% on a year-over-year basis. Analysts forecast that MacroGenics Inc. will post ($1.30) earnings per share for the current fiscal year.

In other MacroGenics news, VP Lynn Cilinski sold 8,922 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $27.22, for a total value of $242,856.84. Following the sale, the vice president now owns 10,845 shares in the company, valued at $295,200.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jon Marc Wigginton sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $30.78, for a total value of $615,600.00. Following the completion of the sale, the senior vice president now owns 20,000 shares in the company, valued at approximately $615,600. The disclosure for this sale can be found here. Corporate insiders own 6.78% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in MGNX. Royal Bank of Canada raised its stake in MacroGenics by 1,122.9% in the second quarter. Royal Bank of Canada now owns 14,430 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 13,250 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in MacroGenics by 19.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 114,901 shares of the biopharmaceutical company’s stock valued at $3,102,000 after buying an additional 18,392 shares in the last quarter. Point72 Asset Management L.P. raised its stake in MacroGenics by 9.6% in the second quarter. Point72 Asset Management L.P. now owns 2,554,900 shares of the biopharmaceutical company’s stock valued at $68,957,000 after buying an additional 224,700 shares in the last quarter. Iguana Healthcare Management LLC acquired a new stake in MacroGenics during the second quarter valued at about $2,024,000. Finally, EverPoint Asset Management LLC raised its stake in MacroGenics by 33.3% in the second quarter. EverPoint Asset Management LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $10,796,000 after buying an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 80.97% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

5 Day Chart for NASDAQ:MGNX

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.